Phase I study of BL22, a recombinant immunotoxin for treatment of CD22+ leukemias and lymphomas.
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2009
At a glance
- Drugs CAT 3888 (Primary)
- Indications Hairy cell leukaemia
- Focus Adverse reactions
- 13 Dec 2008 Actual start date (Dec 1998) added as reported by ClinicalTrials.gov.
- 25 Sep 2005 New trial record.